Nano-Signature Discovery Could Revolutionize Cancer Diagnosis
The new technology has proved to be up to 90% accurate in tests involving 200 human cancer samples and normal DNA.
Read More
Search Results for: prostate cancer
Protagen and German National Center for Tumor Diseases, Heidelberg, to Investigate Immunocompetence of Cancer Patients
Protagen has extended its collaboration with the National Center for Tumor Diseases, Heidelberg, to investigate the immunocompetence of urothelial cancer patients receiving immunotherapy.
Read More
Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies
With further validation, the liquid biopsy test could be used to match metastatic prostate cancer patients to suitable therapies.
Read MoreSignatera Assay Selected for Study of Adjuvant Therapy for Non-Small Cell Lung Cancer
Partners to conduct first study using ctDNA-based minimal residual disease assessment for immunotherapy in the adjuvant non-small cell lung cancer setting.
Read More
Palmetto GBA Issues Draft Local Coverage Determination for Decipher Prostate Biopsy Genomic Classifier
The draft LCD permits coverage for the use of Decipher among men with very low and low risk of prostate cancer according to National Comprehensive Cancer Network guidelines.
Read More